PL2565184T3 - Środek terapeutyczny i środek zapobiegawczy przeciwko chorobie alzheimera - Google Patents
Środek terapeutyczny i środek zapobiegawczy przeciwko chorobie alzheimeraInfo
- Publication number
- PL2565184T3 PL2565184T3 PL11775099T PL11775099T PL2565184T3 PL 2565184 T3 PL2565184 T3 PL 2565184T3 PL 11775099 T PL11775099 T PL 11775099T PL 11775099 T PL11775099 T PL 11775099T PL 2565184 T3 PL2565184 T3 PL 2565184T3
- Authority
- PL
- Poland
- Prior art keywords
- agent
- alzheimer
- disease
- preventative
- therapeutic agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010103246 | 2010-04-28 | ||
| PCT/JP2011/060355 WO2011136318A1 (ja) | 2010-04-28 | 2011-04-28 | アルツハイマー病の治療剤又は予防剤 |
| EP11775099.2A EP2565184B8 (en) | 2010-04-28 | 2011-04-28 | Therapeutic agent and preventative agent for alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2565184T3 true PL2565184T3 (pl) | 2016-06-30 |
Family
ID=44861614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11775099T PL2565184T3 (pl) | 2010-04-28 | 2011-04-28 | Środek terapeutyczny i środek zapobiegawczy przeciwko chorobie alzheimera |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8598212B2 (pl) |
| EP (1) | EP2565184B8 (pl) |
| JP (1) | JP5682555B2 (pl) |
| KR (1) | KR101739881B1 (pl) |
| CN (1) | CN102858748B (pl) |
| AU (1) | AU2011246026B2 (pl) |
| BR (2) | BR122021002784B1 (pl) |
| CA (1) | CA2793859C (pl) |
| ES (1) | ES2560220T3 (pl) |
| MX (1) | MX2012012410A (pl) |
| PL (1) | PL2565184T3 (pl) |
| RU (1) | RU2560171C2 (pl) |
| WO (1) | WO2011136318A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6447496B2 (ja) * | 2014-01-29 | 2019-01-09 | 東レ株式会社 | 多発性硬化症の治療剤又は予防剤 |
| WO2018181859A1 (ja) * | 2017-03-31 | 2018-10-04 | 東レ株式会社 | 抗がん剤誘発末梢神経障害の治療剤又は予防剤 |
| KR102696318B1 (ko) | 2021-04-23 | 2024-08-20 | 주식회사 알트메디칼 | 이소퀴놀린 유도체 화합물을 유효성분으로 포함하는 미토콘드리아 기능이상으로 인한 질환의 예방 또는 치료용 조성물 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6291505B1 (en) | 1998-08-07 | 2001-09-18 | Chiron Corporation | Estrogen receptor modulators |
| AU4308300A (en) | 1999-05-03 | 2000-11-17 | Dr. Reddy's Research Foundation | Pyrazoles having antiinflammatory activity |
| WO2001001986A1 (en) * | 1999-07-02 | 2001-01-11 | Lipton Stuart A | Method of reducing neuronal injury or apoptosis |
| US20040097555A1 (en) * | 2000-12-26 | 2004-05-20 | Shinegori Ohkawa | Concomitant drugs |
| CA2436739A1 (en) * | 2000-12-26 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Combination agent |
| DK1373263T3 (da) * | 2001-04-05 | 2005-03-07 | Torrent Pharmaceuticals Ltd | Heterocycliske forbindelser til aldringsrelaterede og diabetesbetingede vaskulære sygdomme |
| US20040138296A1 (en) * | 2002-08-12 | 2004-07-15 | Pharmacia Corporation | Amyloid immunization and Cox-2 inhibitors for the treatment of alzheimer's disease |
| WO2004021988A2 (en) * | 2002-09-05 | 2004-03-18 | Scios Inc. | Treatment of pain by inhibition of p38 map kinase |
| WO2007111323A1 (ja) | 2006-03-27 | 2007-10-04 | Toray Industries, Inc. | ウレイド誘導体およびその医薬用途 |
| WO2008105383A1 (ja) | 2007-02-26 | 2008-09-04 | Toray Industries, Inc. | ピラゾール誘導体およびその医薬用途 |
| TWI435874B (zh) * | 2008-10-31 | 2014-05-01 | Toray Industries | 環己烷衍生物及其醫藥用途 |
| EP2554541B1 (en) * | 2010-03-31 | 2015-12-09 | Toray Industries, Inc. | Therapeutic agent or prophylactic agent for fibromyalgia |
-
2011
- 2011-04-28 BR BR122021002784-6A patent/BR122021002784B1/pt active IP Right Grant
- 2011-04-28 EP EP11775099.2A patent/EP2565184B8/en not_active Not-in-force
- 2011-04-28 KR KR1020127023063A patent/KR101739881B1/ko active IP Right Grant
- 2011-04-28 WO PCT/JP2011/060355 patent/WO2011136318A1/ja active Application Filing
- 2011-04-28 US US13/643,742 patent/US8598212B2/en active Active
- 2011-04-28 MX MX2012012410A patent/MX2012012410A/es active IP Right Grant
- 2011-04-28 RU RU2012150842/04A patent/RU2560171C2/ru not_active IP Right Cessation
- 2011-04-28 ES ES11775099.2T patent/ES2560220T3/es active Active
- 2011-04-28 PL PL11775099T patent/PL2565184T3/pl unknown
- 2011-04-28 CA CA2793859A patent/CA2793859C/en active Active
- 2011-04-28 BR BR112012024346A patent/BR112012024346A2/pt not_active Application Discontinuation
- 2011-04-28 JP JP2011518618A patent/JP5682555B2/ja not_active Expired - Fee Related
- 2011-04-28 CN CN201180020820.1A patent/CN102858748B/zh not_active Expired - Fee Related
- 2011-04-28 AU AU2011246026A patent/AU2011246026B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130064717A (ko) | 2013-06-18 |
| BR122021002784B1 (pt) | 2021-08-31 |
| CN102858748B (zh) | 2015-06-17 |
| JPWO2011136318A1 (ja) | 2013-07-22 |
| RU2012150842A (ru) | 2014-06-10 |
| MX2012012410A (es) | 2012-12-17 |
| CN102858748A (zh) | 2013-01-02 |
| EP2565184B8 (en) | 2016-03-09 |
| CA2793859C (en) | 2018-02-13 |
| EP2565184A4 (en) | 2013-09-11 |
| KR101739881B1 (ko) | 2017-05-25 |
| CA2793859A1 (en) | 2011-11-03 |
| EP2565184A1 (en) | 2013-03-06 |
| JP5682555B2 (ja) | 2015-03-11 |
| WO2011136318A1 (ja) | 2011-11-03 |
| RU2560171C2 (ru) | 2015-08-20 |
| US8598212B2 (en) | 2013-12-03 |
| EP2565184B1 (en) | 2015-12-30 |
| ES2560220T3 (es) | 2016-02-17 |
| BR112012024346A2 (pt) | 2016-05-24 |
| AU2011246026B2 (en) | 2014-10-30 |
| US20130041158A1 (en) | 2013-02-14 |
| AU2011246026A1 (en) | 2012-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20182069T1 (hr) | Farmaceutski pripravci za liječenje alzheimerove bolesti | |
| HK1246660A1 (zh) | 用於治療阿爾茨海默病的方法和藥物產品 | |
| EP2707369A4 (en) | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | |
| EP2429992A4 (en) | TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER | |
| SG11201403272YA (en) | Compositions and methods for treating alzheimer's disease | |
| EP2485733A4 (en) | METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| ZA201201287B (en) | Therapeutic aryl-amido-aryl compounds and their use | |
| EP2568811A4 (en) | TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER | |
| GB0906159D0 (en) | Drug combination for the treatment of proteostatic diseases | |
| IL237730B (en) | Treatment of mild and moderate Alzheimer's disease | |
| EP2676665A4 (en) | USE OF ALPHA-MANGOSTINE IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF ALZHEIMER | |
| ZA201301458B (en) | Therapeutic agent for pain | |
| EP2554163A4 (en) | THERAPEUTIC ACTIVE FOR NEURODEGENERATIVE DISEASES | |
| SI2424870T1 (sl) | Terapevtska sredstva 713 | |
| EP2660600A4 (en) | DIAGNOSTIC MEDICINE AND DIAGNOSTIC METHOD FOR ALZHEIMER'S DISEASE | |
| EP2829605A4 (en) | PROCESS FOR SCREENING THERAPEUTIC AND / OR PROPHYLACTICS FOR MORBUS ALZHEIMER | |
| EP2667896A4 (en) | METHOD AND COMPOSITION FOR TREATING MORBUS ALZHEIMER | |
| EP2601954A4 (en) | THERAPEUTIC FOR DISEASES | |
| PT2603238E (pt) | Métodos e composições farmacêuticas para o tratamento de uma doença ocular num indíviduo | |
| GB0900484D0 (en) | Therapeutic agent | |
| EP2565184A4 (en) | THERAPEUTIC AGENT AND CONSERVATIVE AGENT AGAINST ALZHEIMER'S DISEASE | |
| EP2517698A4 (en) | ACTIVE AGENT FOR THE TREATMENT OF MORBUS PARKINSON | |
| HK1182712A1 (en) | Therapeutic agents 976 976 | |
| EP2767283A4 (en) | THERAPEUTIC AND PROPHYLACTIC AGAINST DEMYELINISING DISEASE | |
| EP2305629A4 (en) | THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE |